Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J Innovation spotlights its slate of new biotech deals

When Johnson & Johnson Innovation debuted about a year ago, R&D chief Paul Stoffels promised to build an interconnected, global operation that would sink some deep roots into the world's busiest biotech hubs. On Thursday, the group showed off just how far it had come in a short time.

J&J pays $30M to grab rights to Vertex program

With all hands on deck at Vertex focused on the development of a crucial combo drug for cystic fibrosis, the Boston-based biotech has outlicensed an influenza drug to J&J in exchange for a $30 million upfront.

A pair of med tech startups snag J&J deals

Johnson & Johnson committed to financing early stage companies through its Innovation Centers scattered around the globe that launched more than a year ago. Now it's unveiling a dozen alliances that it has made lately with life science companies and research institutions.

J&J Innovation shows off its new summer lineup of biotech deals

Johnson & Johnson Innovation has announced a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers--all aimed at putting the multinational pharma giant on the cutting edge of new product development.

UPDATED: J&J recruits a Hispanic family to be its reps in the Hispanic market

It's no secret that consumers respond to everyday people--just like them--in advertisements. So when Johnson & Johnson wanted to reach out to the Hispanic community, that's just who it set out to find.

Can fake patients still tell tales? In pharma marketing, maybe so

I'm not a doctor, but I play one on TV. That approach has put pharma in the doghouse before. But now, here's a new question. What about, "I'm not a patient, but I play one in a promo campaign for doctors"?

J&J and Glaxo's ViiV venture join up on combo HIV pill

Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet.

J&J teams with Glaxo's ViiV on an HIV combo treatment

Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' dominance in the field.

J&J helps bankroll a $55M gamble on partner Aduro's PhIIb cancer drug study

With the ink still drying on a $365 million deal to in-license rights to a therapeutic cancer vaccine and immunotherapy tech at Aduro BioTech, J&J is back with the news that it is also helping to bankroll the company's research work, jumping into a syndicate which has pledged $55 million to fuel an advanced drug study.

Science pays: 2013's 10 best-compensated R&D chiefs in biopharma

For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>